STOCK TITAN
  1. Home
  2. News
  3. MLTX

MoonLake Immunotherapeutics - MLTX STOCK NEWS

Welcome to our dedicated page for MoonLake Immunotherapeutics news (Ticker: MLTX), a resource for investors and traders seeking the latest updates and insights on MoonLake Immunotherapeutics stock.

MoonLake Immunotherapeutics (symbol: MLTX) is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for immunologic diseases, particularly inflammatory skin and joint conditions. Leveraging its cutting-edge Nanobody® technology, MoonLake aims to create next-level medicines that offer significant improvements over existing therapies.

The company’s flagship product, Sonelokimab, is currently in clinical trials and has shown promising results in treating chronic inflammatory diseases. MoonLake's ARGO trial is a key initiative evaluating the efficacy and safety of Sonelokimab in patients with these debilitating conditions.

Headquartered in the United Kingdom, MoonLake generates the majority of its revenue from this market. The company’s recent Third Quarter 2023 Financial Highlights reflect robust progress, with important upcoming events and clinical data releases anticipated. Additionally, MoonLake’s extensive partnership with healthcare technology platform Komodo Health facilitates the use of real-world data to optimize their drug development processes.

Investors and stakeholders can look forward to MoonLake’s Fourth Quarter and Year-End Financial Results as well as the R&D Day on March 10. These events are expected to provide deeper insights into the company’s ongoing projects and future outlook. With a focus on creating value-driven healthcare solutions, MoonLake is positioned to make significant contributions to the field of immunotherapeutics.

For the latest updates and detailed information, stakeholders are encouraged to follow MoonLake’s news releases and financial disclosures. The company also engages actively in upcoming banking conferences, which provide platforms to discuss their innovative approaches and upcoming milestones.

News

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

Rhea-AI Summary
MoonLake Immunotherapeutics reports positive financial results for 2023, highlights successful Phase 2 trials for sonelokimab, and plans R&D Day. Cash reserves of $511.0 million, R&D Day scheduled for March 10 alongside AAD meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.09%
Tags
earnings
-
News

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

Rhea-AI Summary
MoonLake Immunotherapeutics receives positive feedback from FDA and EMA for Phase 3 program of Nanobody sonelokimab in Hidradenitis Suppurativa, with clear regulatory path outlined. Phase 3 trial to enroll 800 patients, primary endpoint readout expected in mid-2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
clinical trial
-
News

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Rhea-AI Summary
MoonLake Immunotherapeutics (NASDAQ: MLTX) reports Q3 2023 financial results, positive clinical data from global Phase 2 MIRA and ARGO trials for sonelokimab, ending Q3 with $496.0 million in cash. The Nanobody® sonelokimab shows promise in treating hidradenitis suppurativa and psoriatic arthritis. MoonLake is in discussions with regulatory authorities for Phase 3 planning in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
earnings
News

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

Rhea-AI Summary
MoonLake Immunotherapeutics announces positive Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis. Primary endpoint ACR50 met with up to 47% of patients achieving ACR50 at week 12. Other secondary endpoints also reached statistical significance. Discontinuation rate below 4% and safety results consistent with previous studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress

Rhea-AI Summary
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody Sonelokimab for Hidradenitis Suppurativa
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.06%
Tags
clinical trial
-
News

Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress

Rhea-AI Summary
MoonLake announces that Phase 2 MIRA trial results for Nanobody sonelokimab in hidradenitis suppurativa will be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress. The trial achieved positive topline results, making it the first placebo-controlled randomized trial in HS to report positive top-line results. The 24-week Phase 2 MIRA trial data is anticipated soon. Top-line results for MoonLake's Phase 2 ARGO trial in psoriatic arthritis are expected in November.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
clinical trial
News

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

Rhea-AI Summary
MoonLake Immunotherapeutics to host Capital Markets Day on Sep 11. Will discuss psoriatic arthritis market and upcoming trial results. Positive top-line results from Phase 2 MIRA trial in June. External speaker presentation. Q&A session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
conferences
-
News

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

Rhea-AI Summary
MoonLake Immunotherapeutics achieves positive results in Phase 2 MIRA trial for hidradenitis suppurativa, completes randomization in Phase 2 ARGO trial for psoriatic arthritis, and raises $460 million in public follow-on offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
earnings
-
News

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts  

Rhea-AI Summary
MoonLake Immunotherapeutics AG has completed patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA). The randomization target of 200 patients was achieved several weeks ahead of schedule. The top-line 12-week results of the ARGO trial for the novel IL-17A and IL-17F inhibiting Nanobody® sonelokimab are expected in the first half of November 2023, ahead of the American College of Rheumatology Conference. MoonLake also announced a Capital Markets Day on September 11th, 2023, to discuss the PsA market and share expectations on the ARGO readout and an update on the MIRA trial in Hidradenitis Suppurativa (HS). The top-line 24-week data readout for the MIRA trial is now expected in mid-October 2023, following the successful top-line 12-week data readout.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
clinical trial
News

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
offering

FAQ

What is the current stock price of MoonLake Immunotherapeutics (MLTX)?

The current stock price of MoonLake Immunotherapeutics (MLTX) is $52.17 as of December 20, 2024.

What is the market cap of MoonLake Immunotherapeutics (MLTX)?

The market cap of MoonLake Immunotherapeutics (MLTX) is approximately 3.3B.

What does MoonLake Immunotherapeutics specialize in?

MoonLake Immunotherapeutics specializes in developing innovative treatments for immunologic diseases using advanced Nanobody® technology.

What is Sonelokimab?

Sonelokimab is MoonLake's flagship product currently in clinical trials for treating chronic inflammatory skin and joint diseases.

Where is MoonLake Immunotherapeutics headquartered?

MoonLake Immunotherapeutics is headquartered in the United Kingdom.

What is the ARGO trial?

The ARGO trial is a clinical study conducted by MoonLake to evaluate the efficacy and safety of Sonelokimab in patients with inflammatory diseases.

What are MoonLake’s most recent financial highlights?

MoonLake’s most recent financial highlights include the Third Quarter 2023 results, showcasing significant progress and upcoming clinical data releases.

When are MoonLake’s Fourth Quarter and Year-End Financial Results expected?

MoonLake’s Fourth Quarter and Year-End Financial Results are expected to be released in the near future, with further insights provided during their R&D Day on March 10.

What role does Komodo Health play in MoonLake’s operations?

Komodo Health provides real-world data and analytics that support MoonLake’s drug development and optimize healthcare outcomes.

How can I stay updated on MoonLake’s latest news?

You can stay updated on MoonLake’s latest news by following their financial disclosures, news releases, and participating in their events and conferences.

What are some of the upcoming events for MoonLake?

Upcoming events for MoonLake include the R&D Day on March 10 and various banking conferences to discuss their innovative approaches and milestones.

How can I contact MoonLake Immunotherapeutics?

You can contact MoonLake Immunotherapeutics through their investor and media relations teams. For media inquiries, email media@moonlaketx.com.

Stock MLTX logo
MoonLake Immunotherapeutics

Nasdaq:MLTX

MLTX Rankings

#1585 Ranked by Market Cap
N/A Ranked by Dividends

MLTX Stock Data

3.26B
53.63M
15.23%
98.04%
12.69%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
ZUG